Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Theranos Inc.
US IPO Market In 2022 Even Underperformed Normal Years
INFOGRAPHIC: The number of biopharma offerings in 2022 was far below records set in 2020 and 2021, but also below more normal years of 2018 and 2019. The IPO class of 2022 eked out a positive average return, however.
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
NextMed Health Or ‘When Burning Man Meets Health Care At The Beach,’ Just Weeks Away
The XMed conference, now NextMed Health, returns to the Hotel del Coronado with packed programming. Health care innovators will join leaders from industry, governments, organizations and academia to discuss the future of health care.
Financing Quarterly Statistics, Q4 2022
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
- Managed Care, Insurance, Integrated Systems
- Outcomes Studies
- Services sold to health care facilities
- Specialized outpatient services
- Utilization Review, Claims Processing, Cost Contai
Managed Care, Insurance, Integrated Systems
- Specialized Provider Networks
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.